SCHEMBL23629017

SCHEMBL23629017

COC(=O)c1ccc(N)c(OCc2cccs2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DNMT1 P26358 1/20 0.50
KMT2A Q03164 4/20 0.48
L3MBTL1 Q9Y468 3/20 0.48
MEN1 O00255 2/20 0.48
BLM P54132 1/20 0.48
CTDSP1 Q9GZU7 1/20 0.48
TNFRSF1A P19438 1/20 0.46
ALDH1A1 P00352 4/20 0.44
MAPT P10636 3/20 0.44
POLB P06746 2/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC2 Q92769 1/20 0.44
LMNA P02545 1/20 0.44
KDM4E B2RXH2 3/20 0.43
GLA P06280 2/20 0.43
GAA P10253 2/20 0.43
HPGD P15428 1/20 0.43
CASP1 P29466 1/20 0.43
CASP7 P55210 1/20 0.43
ATM Q13315 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23629011 0.81 AR (0.52) DNMT1KMT2AL3MBTL1MEN1BLM
SCHEMBL5805287 0.79 HPGD (0.58) KMT2AL3MBTL1MEN1ALDH1A1MAPT
SCHEMBL23628945 0.78 LOXL2 (0.58) KMT2AL3MBTL1MEN1ALDH1A1MAPT
SCHEMBL23628920 0.78 CYP3A4 (0.46) DNMT1KMT2AL3MBTL1MEN1BLM
SCHEMBL29040749 0.78 DNMT1 (0.56) DNMT1KMT2AL3MBTL1MEN1BLM
SCHEMBL7038132 0.78 ALDH1A1 (0.48) DNMT1KMT2AL3MBTL1MEN1BLM
SCHEMBL23628951 0.78 MRGPRX1 (0.46) L3MBTL1ALDH1A1MAPTLMNAKDM4E
SCHEMBL223446 0.77 HSD17B10 (0.55) KMT2AL3MBTL1MEN1ALDH1A1MAPT
Hydrochloric Acid SCHEMBL7037665 0.77 ALDH1A1 (0.47) DNMT1KMT2AL3MBTL1MEN1BLM
SCHEMBL20602048 0.76 MAPT (0.53) KMT2AL3MBTL1ALDH1A1MAPTHDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12258342-B2 Class of DNA gyrase and/or topoisomerase IV inhibitors with activity against gram-positive and gram-negative bacteria UNIVERZA V LJUBLJANI (SI) 2025-03-25 US disclosed
US-20250002455-A1 NEW N-PHENYLPYRROLAMIDE INHIBITORS OF DNA GYRASE AND TOPOISOMERASE IV WITH ANTIBACTERIAL ACTIVITY UNIV LJUBLJANI (SI) 2025-01-02 US disclosed
EP-4263503-A1 NEW N-PHENYLPYRROLAMIDE INHIBITORS OF DNA GYRASE AND TOPOISOMERASE IV WITH ANTIBACTERIAL ACTIVITY Univerza V Ljubljani (SI) 2023-10-25 EP disclosed
WO-2022129327-A1 NEW N-PHENYLPYRROLAMIDE INHIBITORS OF DNA GYRASE AND TOPOISOMERASE IV WITH ANTIBACTERIAL ACTIVITY UNIVERZA V LJUBLJANI (SI) 2022-06-23 WO disclosed
US-20210323957-A1 NEW CLASS OF DNA GYRASE AND/OR TOPOISOMERASE IV INHIBITORS WITH ACTIVITY AGAINST GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA UNIVERZA V LJUBLJANI (SI) 2021-10-21 US disclosed
EP-3847172-A1 NEW CLASS OF DNA GYRASE AND/OR TOPOISOMERASE IV INHIBITORS WITH ACTIVITY AGAINST GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA Univerza v Ljubljani (SI) 2021-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250002455-A1 NEW N-PHENYLPYRROLAMIDE INHIBITORS OF DNA GYRASE AND TOPOISOMERASE IV WITH ANTIBACTERIAL ACTIVITY TOP1, TOP2A, TOP2B DNMT1 347/4885KMT2A 1699/4885L3MBTL1 3940/4885
US-20210323957-A1 NEW CLASS OF DNA GYRASE AND/OR TOPOISOMERASE IV INHIBITORS WITH ACTIVITY AGAINST GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA TOP1, TOP2A, TOP2B DNMT1 185/4885KMT2A 2573/4885L3MBTL1 3983/4885
US-12258342-B2 Class of DNA gyrase and/or topoisomerase IV inhibitors with activity against gram-positive and gram-negative bacteria TOP1, TOP2A, TOP2B DNMT1 221/4885KMT2A 2632/4885L3MBTL1 3585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.